Protective immunization against melanoma by gp100 DNA–HVJ-liposome vaccine

Zhou, Wenzhong; Kaneda, Yasufumi; Huang, Sharon K.; Morishita, Ryuichi; Hoon, Dave S.B.

doi:10.1038/sj.gt.3300998

Cited by 30 publications

(14 citation statements)

References 21 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, the weak antigenicity of many tumor antigens requires the association with robust adjuvants to boost the cell-mediated immune response 40 . In our experiment, β-SQDG18 ( 6 ) was tested in mice challenged with the human gp100 25–33 (hgp100 25–33 ) peptide, an antigen derived from a melanocyte differentiation protein 41, 42 . The adjuvant effect of β-SQDG18 ( 6 ) was compared with those of Freund’s and CpG Oligodeoxynucleotide (CpG) adjuvants.…”

Section: Resultsmentioning

confidence: 99%

A new marine-derived sulfoglycolipid triggers dendritic cell activation and immune adjuvant response

Manzo

Cutignano

Pagano

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Dendritic Cells (DCs) recognize infectious non-self molecules and engage the adaptive immune system thereby initiating long lasting, antigen-specific responses. As such, the ability to activate DCs is considered a key tool to enhance the efficacy and quality of vaccination. Here we report a novel immunomodulatory sulfolipid named β-SQDG18 that prototypes a class of natural-derived glycolipids able to prime human DCs by a TLR2/TLR4-independent mechanism and trigger an efficient immune response in vivo. β-SQDG18 induces maturation of DC with the upregulation of MHC II molecules and co-stimulatory proteins (CD83, CD86), as well as pro-inflammatory cytokines (IL-12 and INF-γ). Mice immunized with OVA associated to β-SQDG18 (1:500) produced a titer of anti-OVA Ig comparable to traditional adjuvants. In an experimental model of melanoma, vaccination of C57BL/6 mice with β-SQDG18-adjuvanted hgp10 peptide elicited a protective response with a reduction in tumour growth and increase in survival.

show abstract

Section: Resultsmentioning

confidence: 99%

A new marine-derived sulfoglycolipid triggers dendritic cell activation and immune adjuvant response

Manzo

Cutignano

Pagano

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…[21][22][23] Thus, many alternate approaches to enhance cellular uptake of the injected DNA have been used, including particle-mediated DNA delivery (gene gun), 16,24 intramuscular electric gene transfer, 25 biodegradable aliginate microspheres, 26 attenuated intracellular bacteria, 27 cationic lipid/DNA complex or cationic liposome encapsulated DNA, [28][29][30][31] and virosome encapsulated DNA. 32,33 Among these, cationic liposome and cationic lipid/DNA complexes have demonstrated their ability to enhance DNA transfer 34 and to modulate immune responses against tumor 29,30,35 and HBV. 36 In this paper, cationic liposomes composed of different cationic lipids were used to mediate DNA immunization in mice, and their efficiencies were compared.…”

mentioning

confidence: 99%

Modulation of cellular immune response against hepatitis C virus nonstructural protein 3 by cationic liposome encapsulated DNA immunization

et al. 2003

View full text Add to dashboard Cite

A vaccine strategy directed to increase Th1 cellular immune responses, particularly to hepatitis C virus (HCV) nonstructural protein 3 (NS3), has considerable potential to overcome the infection with HCV. DNA vaccination can induce both humoral and cellular immune responses, but it became apparent that the cellular uptake of naked DNA injected into muscle was not very efficient, as much of the DNA is degraded by interstitial nucleases before it reaches the nucleus for transcription. In this paper, cationic liposomes composed of different cationic lipids, such as dimethyl-dioctadecylammonium bromide (DDAB), 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), or 1,2-dioleoyl-sn-glycerol-3-ethylphosphocholine (DOEPC), were used to improve DNA immunization in mice, and their efficiencies were compared. It was found that cationic liposome-mediated DNA immunization induced stronger HCV NS3-specific immune responses than immunization with naked DNA alone. Cationic liposomes composed of DDAB and equimolar of a neutral lipid, egg yolk phosphatidylcholine (EPC), induced the strongest antigen-specific Th1 type immune responses among the cationic liposome investigated, whereas the liposomes composed of 2 cationic lipids, DDAB and DOEPC, induced an antigen-specific Th2 type immune response. All cationic liposomes used in this study triggered high-level, nonspecific IL-12 production in mice, a feature important for the development of maximum Th1 immune responses. In conclusion, the cationic liposome-mediated gene delivery is a viable HCV vaccine strategy that should be further tested in the chimpanzee model. (HEPATOLOGY 2003;37: 452-460.)

show abstract

“…The reactivation system will be used for the effective immunization of animals with DNA cancer vaccines. We have succeeded in preventing melanom a growth in mice by vaccination with melanoma-spe cific gp100 DNA (Zhou et al, 1999). Vaccination with oriP-gp100 expression plasmid combined with an EBNA-1 expression vector will be able to induce more effective immunization of mice with the tumor antigen by reactivation of gp100 expression.…”

Section: Discussionmentioning

confidence: 96%

Enhancement of Transgene Expression by Cotransfection of oriP Plasmid with EBNA-1 Expression Vector

Kaneda

Saeki²,

Nakabayashi³

et al. 2000

Human Gene Therapy

View full text Add to dashboard Cite

We have attempted to develop a system for specific enhancement of transgene expression, which has been one of the most important issues in human gene therapy. When an Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA-1) expression vector, pCMV-trEBNA-1, was cotransfected with an origin of latent viral DNA replication (oriP)-harboring plasmid, poriP-CMV-luciferase, luciferase gene expression was up to 20 times greater than in the absence of EBNA-1. This enhancement was regulated mainly at the transcriptional level and was dependent on the oriP sequence and the amount of EBNA-1. However, cointroduction of poriP-CMV-luciferase with purified recombinant EBNA-1 inhibited luciferase gene expression whereas no inhibition was observed when pCMV-luciferase was cointroduced with recombinant EBNA-1. We also introduced poriP-CMV-luciferase into mouse liver via the use of HVJ (hemagglutinating virus of Japan)-liposomes. By 10 days after transfer, luciferase gene expression was decreased to low levels. We then introduced pCMV-trEBNA-1 to mouse liver via HVJ-liposomes on day 10. Luciferase gene expression was reactivated, whereas no reactivation was detected by the injection of EBNA-1 expression plasmid into liver injected with pCMV-luciferase lacking the oriP sequence. Thus, cotransfection of oriP-harboring expression vector with EBNA-1 expression plasmid should be promising for human gene therapy, although the safety of the system must be investigated thoroughly.

show abstract

Protective immunization against melanoma by gp100 DNA–HVJ-liposome vaccine

Cited by 30 publications

References 21 publications

A new marine-derived sulfoglycolipid triggers dendritic cell activation and immune adjuvant response

A new marine-derived sulfoglycolipid triggers dendritic cell activation and immune adjuvant response

Modulation of cellular immune response against hepatitis C virus nonstructural protein 3 by cationic liposome encapsulated DNA immunization

Enhancement of Transgene Expression by Cotransfection of oriP Plasmid with EBNA-1 Expression Vector

Contact Info

Product

Resources

About